Here are four notes:
1. Exogen has treated over 1 million patients since being FDA PMA approved in 1994.
2. The system uses low-intensity pulsed ultrasound to stimulate the body’s natural healing process.
3. The new clinical research, Bioventus Observational Non-interventional Exogen Studies, will build on previous data to develop additional clinical knowledge of the product.
4. Bioventus Senior Vice President and Chief Science Offer Alessandro Pavesio said, “BONES represents a significant investment in developing epidemiologically grounded rigorous clinical evidence to support use of Exogen in fractures at risk.”
More device articles:
Baxter’s FLOSEAL may yield cost savings for hospital spinal, cardiac surgeries: 4 things to know
Mizuho OSI opens 4th global training center — 5 details
Medacta reaffirms partnership with OREF — 5 observations
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
